Cargando…
Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature
BACKGROUND: WHO’s Global Programme to Eliminate Lymphatic Filariasis (LF) uses mass drug administration (MDA) of anthelmintic medications to interrupt LF transmission in endemic areas. Recently, a single dose combination of ivermectin (IVM), diethylcarbamazine (DEC), and albendazole (ALB) was shown...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973625/ https://www.ncbi.nlm.nih.gov/pubmed/29768412 http://dx.doi.org/10.1371/journal.pntd.0006454 |
_version_ | 1783326670279671808 |
---|---|
author | Budge, Philip J. Herbert, Carly Andersen, Britt J. Weil, Gary J. |
author_facet | Budge, Philip J. Herbert, Carly Andersen, Britt J. Weil, Gary J. |
author_sort | Budge, Philip J. |
collection | PubMed |
description | BACKGROUND: WHO’s Global Programme to Eliminate Lymphatic Filariasis (LF) uses mass drug administration (MDA) of anthelmintic medications to interrupt LF transmission in endemic areas. Recently, a single dose combination of ivermectin (IVM), diethylcarbamazine (DEC), and albendazole (ALB) was shown to be markedly more effective than the standard two-drug regimens (DEC or IVM, plus ALB) for achieving long-term clearance of microfilaremia. OBJECTIVE AND METHODS: To provide context for the results of a large-scale, international safety trial of MDA using triple drug therapy, we searched Ovid Medline for studies published from 1985–2017 that reported adverse events (AEs) following treatment of LF with IVM, DEC, ALB, or any combination of these medications. Studies that reported AE rates by treatment group were included. FINDINGS: We reviewed 162 published manuscripts, 55 of which met inclusion criteria. Among these, 34 were clinic or hospital-based clinical trials, and 21 were community-based studies. Reported AE rates varied widely. The median AE rate following DEC or IVM treatment was greater than 60% among microfilaremic participants and less than 10% in persons without microfilaremia. The most common AEs reported were fever, headache, myalgia or arthralgia, fatigue, and malaise. INTERPRETATION: Mild to moderate systemic AEs related to death of microfilariae are common following LF treatment. Post-treatment AEs are transient and rarely severe or serious. Comparison of AE rates from different community studies is difficult due to inconsistent AE reporting, varied infection rates, and varied intensity of follow-up. A more uniform approach for assessing and reporting AEs in LF community treatment studies would be helpful. |
format | Online Article Text |
id | pubmed-5973625 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-59736252018-06-08 Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature Budge, Philip J. Herbert, Carly Andersen, Britt J. Weil, Gary J. PLoS Negl Trop Dis Research Article BACKGROUND: WHO’s Global Programme to Eliminate Lymphatic Filariasis (LF) uses mass drug administration (MDA) of anthelmintic medications to interrupt LF transmission in endemic areas. Recently, a single dose combination of ivermectin (IVM), diethylcarbamazine (DEC), and albendazole (ALB) was shown to be markedly more effective than the standard two-drug regimens (DEC or IVM, plus ALB) for achieving long-term clearance of microfilaremia. OBJECTIVE AND METHODS: To provide context for the results of a large-scale, international safety trial of MDA using triple drug therapy, we searched Ovid Medline for studies published from 1985–2017 that reported adverse events (AEs) following treatment of LF with IVM, DEC, ALB, or any combination of these medications. Studies that reported AE rates by treatment group were included. FINDINGS: We reviewed 162 published manuscripts, 55 of which met inclusion criteria. Among these, 34 were clinic or hospital-based clinical trials, and 21 were community-based studies. Reported AE rates varied widely. The median AE rate following DEC or IVM treatment was greater than 60% among microfilaremic participants and less than 10% in persons without microfilaremia. The most common AEs reported were fever, headache, myalgia or arthralgia, fatigue, and malaise. INTERPRETATION: Mild to moderate systemic AEs related to death of microfilariae are common following LF treatment. Post-treatment AEs are transient and rarely severe or serious. Comparison of AE rates from different community studies is difficult due to inconsistent AE reporting, varied infection rates, and varied intensity of follow-up. A more uniform approach for assessing and reporting AEs in LF community treatment studies would be helpful. Public Library of Science 2018-05-16 /pmc/articles/PMC5973625/ /pubmed/29768412 http://dx.doi.org/10.1371/journal.pntd.0006454 Text en © 2018 Budge et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Budge, Philip J. Herbert, Carly Andersen, Britt J. Weil, Gary J. Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature |
title | Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature |
title_full | Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature |
title_fullStr | Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature |
title_full_unstemmed | Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature |
title_short | Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature |
title_sort | adverse events following single dose treatment of lymphatic filariasis: observations from a review of the literature |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973625/ https://www.ncbi.nlm.nih.gov/pubmed/29768412 http://dx.doi.org/10.1371/journal.pntd.0006454 |
work_keys_str_mv | AT budgephilipj adverseeventsfollowingsingledosetreatmentoflymphaticfilariasisobservationsfromareviewoftheliterature AT herbertcarly adverseeventsfollowingsingledosetreatmentoflymphaticfilariasisobservationsfromareviewoftheliterature AT andersenbrittj adverseeventsfollowingsingledosetreatmentoflymphaticfilariasisobservationsfromareviewoftheliterature AT weilgaryj adverseeventsfollowingsingledosetreatmentoflymphaticfilariasisobservationsfromareviewoftheliterature |